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Abstract
Objectives Irreversible electroporation (IRE) is an ablative
therapy with a low side-effect profile in prostate cancer. The
objective was: 1) To compare the volumetric IRE ablation
zone on grey-scale transrectal ultrasound (TRUS), contrast-
enhanced ultrasound (CEUS) and multiparametric MRI
(mpMRI) with histopathology findings; 2) To determine a
reliable imaging modality to visualize the IRE ablation effects
accurately.
Methods A prospective phase I-II study was performed in 16
patients scheduled for radical prostatectomy (RP). IRE of the
prostate was performed 4 weeks before RP. Prior to, and
4 weeks after the IRE treatment, imaging was performed by
TRUS, CEUS, and mpMRI. 3D-analysis of the ablation vol-
umes on imaging and on H&E-stained whole-mount sections
was performed. The volumes were compared and the correla-
tion was calculated.
Results Evaluation of the imaging demonstrated that with T2-
weighted MRI, dynamic contrast enhanced (DCE) MRI, and
CEUS, effects of IRE are visible. T2MRI and CEUS closely
match the volumes on histopathology (Pearson correlation r=
0.88 resp. 0.80). However, IRE is not visible with TRUS.
Conclusions mpMRI and CEUS are appropriate for assessing
IRE effects and are the most feasible imaging modalities to
visualize IRE ablation zone. The imaging is concordant with
results of histopathological examination.
Key points
• mpMRI and contrast-enhanced ultrasound are appropriate
imaging modalities for assessing IRE effects
• mpMRI and CEUS are the most feasible imaging modalities
to visualize IRE ablation zone
• The imaging is concordant with results of histopathological
examination after IRE
• Grey-scale US is insufficient for assessing IRE ablations
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Prostate cancer (Pca) is the most prevalent cancer in males in
the Western world and the second most common cause of
cancer death. Nevertheless, the majority of the patients will
either have their cancer successfully cured or will die with
rather than because of prostate cancer [1]. Since the liberal
use of prostate-specific antigen tests and Pca screening began,
the incidence of Pca diagnosis has increased substantially. Pca
is traditionally managed by active surveillance or radical treat-
ments, including radical prostatectomy and radiation therapy
[2]. These radical methods often cause concomitant damage to
prostate adjacent tissues, resulting in side-effects which in-
clude urinary incontinence (9.4–18.3 %), impotence (40–
95 %) and bowel complications (21.9–35.8 %) [3]. Nowa-
days, the concept of ablative therapy emerges as an approach
positioned between expectant management and radical thera-
py in order to provide effective treatment while minimizing
morbidity [4, 5]. In a select group of patients with localized
low- and intermediate-risk Pca, ablative therapy might be a
more suitable therapeutic option than total gland treatment.
The clear purpose is to reduce the toxicity of organ-confined
Pca treatments while adequately treating the cancer.
Irreversible electroporation (IRE) is an ablative technology
that uses high voltage, low energy direct current, travelling
between at least two electrodes. The electric current causes
pore formation in the cell membrane that leads to permanent
defects that result in cell death [6]. Literature on IRE reports
advantages by sparing neighbouring vital structures such as
the urethra, blood vessels and nerves [7, 8]. These properties
could help to reduce, or even avoid, side effects.
For focal therapy, high quality imaging is of paramount
importance for several reasons. The tumour should be identi-
fied and extracapsular extension should be excluded. During
treatment, the urologist should be confident that the identified
tumour area is completely ablated and no significant volume
of tumour resides outside the targeted zone. During follow-up,
recurrences or residual tumour should be recognized [9]. No
literature is available on the role of imaging in follow-up of
IRE in prostates. It is unclear what is to expect as image within
state-of-the-art imaging modalities like greyscale transrectal
ultrasound (TRUS), contrast-enhanced ultrasound (CEUS)
or any multiparametric MRI (mpMRI) modality. We hypoth-
esize that 1) TRUS, CEUS and mpMRI are feasible to identify
the focal IRE ablation zone in 3D; and 2) ablation zones iden-
tified on imaging are comparable to histopathology.
The aim of this study is to identify appropriate methods for
the assessment of the IRE treatment zone and to determine
which imaging modality (TRUS, CEUS or mpMRI) is feasi-
ble to accurately visualize the focal IRE ablation effect in 3D.
Materials and methods
A prospective study was conducted in 16 patients with con-
firmed organ-confined prostate cancer who were scheduled
for radical prostatectomy (RP). Inclusion and exclusion
criteria are listed in Table 1. The patients underwent a focal
IRE procedure approximately one month prior to the surgery.
mpMRI [by means of T2-weighted imaging (T2W), dynamic
contrast-enhanced imaging (DCE) and diffusion-weighted im-
aging (DWI)], TRUS, and CEUS imaging were performed
prior to the IRE procedure and approximately 4 weeks after
the IRE treatment, on the day of admission for the RP. Patient
characteristics are presented in Table 2. The study was con-
ducted in two participating centres: AMCUniversity Hospital,
Amsterdam, and Sismanoglio University Hospital, Athens.
The study was approved by the two individual research ethics
committees and registered in the clinicaltrials.gov database
(NCT01790451). The trial was executed according to the
study protocol previously reported in Van den Bos et al. [10].
IRE
The IRE procedures were performed using the Nanoknife®
IRE system (AngioDynamics Inc, Queensbury, NY) under
general anaesthesia and full paralysis. The electrodes were
placed transperineally in the prostate under ultrasound guid-
ance (Fig. 1), delivering 90 pulses of 90 μs duration each with
an electric field of on average 1500 Volt (V) per cm distance
between the electrodes (voltage-to-distance ratio). The stan-
dard setting of 1500 V/cm was adapted when the current
showed a constant low amperage or high amperage ranging
from 1200 to 2100 V/cm (Table 3). This was the initial expe-
rience of IRE in both participating centres. The number and
configuration of the electrodes were varied to assess the effect
on the ablation area. The electrodes were placed in the lobe
found most positive biopsies. Therefore, exact targeting of the
tumour was not pursued.
In the first patient, the IRE procedure was performed using
two electrodes. Five patients were treated with three elec-
trodes and ten patients with four electrodes or more. In patient
6, a pullback of 15 mm of the electrodes was performed after
the first ablation cycle. In patient 8, the two lateral electrodes
were repositioned to the other lobe after one ablation cycle, in
order to perform a bilateral ablation. Additional details about
the device and procedures are described in BMJ Open [10].
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Greyscale transrectal ultrasound
Greyscale TRUS scanning was performed in all 16 patients
before the IRE procedure and 4 weeks after IRE. Patients were
scanned in Amsterdam using a Philips IU22 Ultrasound sys-
tem with an end-firing transrectal probe (Phillips Healthcare,
Bothell, WA, USA) and in Athens using a Falcon 2101 EXCL
(BK Medical, MA, USA) while positioned in the left lateral
decubitus position. Greyscale TRUS standard volumetry was
performed, followed by three sweeps for later 3D reconstruc-
tion, consisting of a transversal sweep from base to apex, a
longitudinal sweep from base to apex, and a longitudinal
sweep from left to right.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Patients with prostate cancer with indication for radical prostatectomy
Life expectancy>10 years
Able to visualize prostate gland adequately on transrectal US imaging
No prostate calcification greater than 5 mm
Ability of subject to stop anticoagulant and anti-platelet therapy for
7 days prior and 7 days post procedure
Exclusion criteria
Bleeding disorders
Active urinary tract infection
History of bladder neck contracture
Inflammatory bowel diseases
Concurrent major debilitating illness
ICD / Pacemaker /Cardiac History
Prior or concurrent malignancy
Biologic therapy for prostate cancer
Chemotherapy for prostate cancer
Hormonal therapy for prostate cancer within 3 months of procedure
Radiotherapy for prostate cancer
Transurethral prostatectomy or urethral stent
Prior major rectal surgery
Table 2 Patient characteristics
Patient No. Age Tumour stage Gleason score in biopsies PSA at diagnosis
1 63 T2b 4+3 13.1
2 54 T2c 4+3 5.8
3 70 T2b 3+3 5
4 65 T2c 3+3 9.6
5 48 T2a 4+4 4.4
6 69 T2a 3+3 13
7 44 T2b 3+3 3.6
8 69 T2c 3+3 5.7
9 56 T2c 3+3 8.7
10 75 T1c 4+3 15.5
11 50 T1c 3+4 5.3
12 73 T2a 3+4 25
13 49 T2c 3+4 7
14 54 T1c 3+3 8
15 60 T1c 3+3 5.8
16 63 T2c 4+4 10.1
Fig. 1 Patient positioned in high-lithotomy position with three
ultrasound-guided transperineally inserted electrodes
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Contrast-enhanced ultrasound
Subsequently, CEUS recordings were acquired before and
4 weeks after IRE in the 12 patients treated in Amsterdam.
CEUS imaging was performed with the same Philips IU22
machine using the protocol described by Kuenen et al. [11]
with an ultrasound contrast agent that consists of gas-filled
microbubbles, which are stabilised by a protein or lipid shell
(Sonovue®, Bracco, Milan, Italy). The prostate was scanned
in four planes: base, base-mid, mid-apex, and apex. For each
plane, recordings were completed after a bolus injection
2.4 mL of UCA followed by a 5 mL saline flush. Subsequent-
ly, transversal sweeps from base to apex were performed to
allow calculation of the dimensions of the contrast deficits
after IRE.
Multiparametric MRI
Two mpMRI studies were performed per patient. The
first was acquired prior to the IRE procedure and the
second was performed, 4 weeks after the IRE treatment
and 1 day prior to RP. The mpMRIs were made accord-
ing to the ESUR guidelines [12]. All patients included
in the AMC Amsterdam (n=12 patients) underwent
mpMRI performed on a 1.5 Tesla AVANTO® MRI
scanner (Siemens Healthcare, Erlangen, Germany) using
an integrated endorectal-pelvic phased-array coil
(Medrad, Warrendale, USA).[13] The mpMRI protocol
in Athens (n=4 patients) was performed on a 3.0 tesla
MAGNETOM Trio (Siemens, Healthcare, Erlangen,
Germany) with a pelvic phased-array coil. In the
AMC, first, T2 weighted turbospin echo sequences were
performed in axial, coronal, and sagittal planes, cover-
ing the prostate and seminal vesicles. Second, a single-
shot-echo-planar imaging sequence with diffusion mod-
ule and fat suppression pulse was implemented. ADC
maps were automatically calculated by the scanner soft-
ware, using all three b-values. Next, dynamic gadolini-
um enhanced MRI was performed using fast gradient
echo sequences. Seven slices covering the prostate were
acquired with a temporal resolution of seven slices per
2.1 seconds before and 90 seconds after intravenous
admin i s t r a t ion of 0 .1 mmol of gadopen te ta t e
dimeglumine per kg of body weight Gadolinium DTPA
(Gadovist). To suppress bowel peristalsis, intravenous or
intramuscular administration of 20 mg Buscopan® was
given. In Athens at 3T, first T2-weighted turbospin echo
sequences were performed in transverse, coronal and
sagittal directions. Next, single-shot-echo-planar imaging
sequences with diffusion module and fat suppression
pulse were implemented. ADC maps were automatically
calculated by the scanner software using two b-values.
Finally, dynamic contrast-enhanced MRI was performed
using fast gradient echo sequences with a similar tem-
poral resolution as in the AMC.
3D assessment of imaging
The pre- and post-treatment images of the prostates
were examined in consensus by two uro-radiologists of
the AMC, blinded to pathology results. Cross-sectional
images from TRUS, CEUS, and mpMRI were visually
inspected for lesion boundaries and contrast differences.
The ablation zones were volumetrically evaluated in
Table 3 Procedure specifications
per patient Patient No. Volume prostate (mL) Number of electrodes Voltage-to-distance ratio (V/cm)
1 50 2 1500
2 30 3 1500–1700
3 57 4 1500
4 60 4 1200–1500
5 19 3 1500–1800
6 42 4 + pullback 1350–1500
7 21 3 1500–1650
8 40 6 1350–1500
9 50 4 1500–1800
10 37 4 1500
11 25 3 1500–1800
12 50 4 1500–1650
13 28 4 1500–1800
14 36 4 1500–1950
15 31 3 1500–2100
16 48 3 1500
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CEUS and T2 MRI data. For MRI, the ablation zones
were manually segmented frame by frame, using a de-
lineation tool using Amira®. For CEUS, the ablation
zones were automatically segmented in 3D using aver-
aging, window levelling and wand tracing in ImageJ/
FIJI [14], or manually, frame by frame using a delinea-
tion tool. The precisely outlined areas were segmented
and aligned to create a 3D reconstruction of the ablation
zones, and the volumes were determined using AMIRA
shape-analysis package software (Version 5.5; FEI Visu-
alization Sciences Group, Mérignac Cédex, France).
Histopathology
To ensure consistency of histopathological analysis, examina-
tion of the prostate specimens from both centres was
performed at the pathology department of the AMC. The se-
rial sections of 3–5 mm were cut perpendicular to the rectum
according to the axial MRI plane, followed by a surface cut of
each slice, and these were inspected macroscopically and doc-
umented by photography. Whole-mount slices from apex to
base were embedded in paraffin; 4-μm-thick sections were cut
and examined with H&E staining. The boundaries of the ab-
lation zone were determinedmanually using light microscopy,
and marked on the slides. The outlined slides were scanned
with an IntelliSite Ultra-Fast Scanner (Philips, Best, the Neth-
erlands), and the volumes of tissue alterations were defined by
segmentation as indicated by the pathologist, followed
by volumetric shape analysis in AMIRA. The acquired
volumes were adjusted for shrinkage during fixation
using the pre-fixation prostate dimensions divided by
the post-fixation volume.
Fig. 2 Imaging modalities pre-
IRE (left) and 4 weeks post-IRE
(right): a. Grey-scale ultrasound;
cannot image the ablation zone. b.
CEUS; shows a sharp-demarcated
dark area presenting non-perfused
tissue. c. DCE-MRI shows a
sharp-delineated non-enhancing
lesion. d. T2-weighted MRI
shows hypo intense lesion
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Data analysis
All extracted volumes of CEUS, T2MRI and PAwere directly
compared and visualised using an x/y scatterplot. The scatter
data was linearly fitted, from which a Pearson correlation val-
ue (goodness of fit, r) and slope were calculated as measures
of correlation. All the images were matched with the PA vol-
umes. To calculate the error per 3D reconstruction for CEUS,
T2MRI and PA, the lesion volumewas divided by the number
of slices from which the 3D data set was constructed.
Results
Procedural results
No serious adverse event was observed during the procedure
or hospital stay. All patients, except for one due to social
reasons, were discharged from the hospital 1 day after the
IRE treatment.
Qualitative evaluation of imaging
Qualitative evaluations of the imaging modalities
showed that grey-scale TRUS inadequately visualized
IRE ablation effects in all 16 cases. All post-IRE CEUS
provided a clear, dynamic, homogeneous, non-perfused
image of the ablation zone in all patients, except for the
first treated patient, in which no non-perfused area
could be detected. In nine out of 12 scans, the data
set was sufficient to reconstruct the ablation zone in 3D.
On T1-dynamic scans, the IRE effects are identifiable as
areas of non-contrast enhancement. On T2W images, 15 pa-
tients showed heterogeneous signal intensity and nine patients
showed marked hypo-intense margins suggestive of fibrosis.
The mpMRI of the first patient did not show a clear ablation
zone. Three of the patients had a slightly higher intralesional
T2-signal intensity, possibly because of oedema. Twelve pa-
tients had high signal intensity focal intralesional areas due to
haemorrhage on the pre-contrast T1-weighted images. TRUS
and CEUS images were simultaneously acquired and are
therefore automatically matched. mpMRI images were visu-
ally matched to the CEUS data (Fig. 2). Three-dimensional
reconstructions are shown in Fig. 3.
Qualitative evaluation of histopathology
Macroscopic assessment showed, in 15 cases, lesions in
the treated zone with a central white necrotic zone
surrounded by an outer, dark red haemorrhagic zone
(Fig. 4). Microscopic assessment showed, in the same
15 cases, fibrotic and necrotic areas with mild inflamma-
tion with sharp demarcations. The prostate specimen of
the first treated patient contained solely fibrotic tissue in
a bilateral pattern without any necrotic component, not
showing any relation to the unilateral electrode configu-
ration. This suggests that the fibrosis was pre-existent and
Fig. 3 1. PAwhole-mount slide
with delineated ablation zone
(dotted line) and 3D
reconstruction of ablation zone. 2.
T2-MRI with 3D-recontruction of
prostate and ablation zone. 3.
CEUS of prostate with 3D-
recontruction of ablation zone
Eur Radiol (2016) 26:2252–2260 2257




Comparison of the ablation zones volumes traced on the post-
IRE T2-weighted MR images with the ablated volume traced
on H&E stained PA images revealed that MRI-measured vol-
umes were 1.16 times the PA measurements. The Pearson
correlation index between the two sets of measurements was
r=0.88 with a slope of 0.75 (Fig. 5A).
CEUS–PA correlation
Ablation zone volumes traced on the post-IRE CEUS images
compared with volumes traced on H&E PA images showed
that, on average, CEUS volumes were 1.57 times greater than
PA measurements. The Pearson correlation index between
these sets of measurements was r=0.80 with a slope of 0.82
(Fig. 5B). The errors on CEUS values were too small to dis-
play in the graph.
Discussion
This is the first study assessing three different imaging modal-
ities pre- and post-IRE treatment for prostate cancer. This
study demonstrated that either mpMRI or CEUS can be used
to accurately and reliably follow the area treated with IRE.
Lindner et al. published a similar designed case-study with
focal laser ablation [15]. Comparison of the ablated volume
traced on H&E stained PA with the volumes traced on MRI
revealed on average that MRI-measured volumes were 1.4
times PA measurements with a Pearson correlation index of
r=0.79. Grampsas et al. published a comparable trial with
cryoablation, concluding that TRUS overestimates the area
of prostatic tissue destroyed by the ablation, and this chal-
lenges the assumption that the entire prostate is lethally frozen
when its boundaries are included within the hypoechoic ice
ball observed on TRUS [16]. Several studies have been per-
formed using high-intensity focused ultrasound (HIFU)
Fig. 5 Correlation of ablation volumes T2-weighted MRI and H&E
pathology (A). The Pearson correlation index between the two sets of
measurements was r=0.88 with a slope of 0.75. Correlation of ablation
volumes CEUS and H&E pathology (B). The Pearson correlation index
between these sets of measurements is r=0.80 with a slope of 0.82. The
errors on CEUS values are too small to display in the graph
Fig. 4 Macroscopic fixed 4-mm-
thick prostate slice and whole-
mount PA coupe with H&E
staining
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followed by RP. Madersbacher et al. demonstrated that HIFU
induced sharply delineated intraprostatic coagulative necrosis
within the target area, whereas alterations of periprostatic
structures were never observed [17]. The histopathological
effects of IRE in correlation with treatment planning and
probe placement, in addition to effects to the prostate capsule,
urethra and neurovascular bundle, were recently described by
Van den Bos et al. [18]. Beerlage et al. showed PA reports of
radical prostatectomy specimens following HIFU treatment
with marked and complete necrosis in the treated area [19,
20]. None of these studies include post-treatment imaging
assessing the ablation effects during follow-up.
A limitation of the present study is the low number of
CEUS data sets available for analysis. Because CEUS could
only be obtained in Amsterdam, CEUS analysis was done
using the data of 12 patients. In nine patients, 3D reconstruc-
tions could be made using the CEUS data. In the remaining
four scans, the transversal sweep was insufficient for a reliable
3D analysis. Wiggerman et al. performed CEUS immediately
after and 20 minutes after IRE of hepatic tumours and con-
cluded that CEUS allowed good prediction of ablation result
following IRE [21]. Furthermore, at this early phase of re-
search, the IRE treatments were performed without curative
intent. So within the trial, the efficacy for treatment of prostate
cancer could not yet be assessed. Another limitation is that the
fixated prostates were cut by hand, possibly leading to reduc-
tion of the correlation between the imaging and PA.
In the analysis of the PA, the prostate specimen of the first
patient (treated with a two-electrode configuration) showed
confluent fibrotic tissue without a necrotic component, in con-
trast to all other specimens that contained a necrotic focus.
Additionally, the IRE treatment was performed unilaterally,
yet the fibrosis was present in both lobes and was therefore
considered as pre-existent, as associated with chronic inflam-
mation and aging. Together with the additional absence of in-
field necrotic tissue, the patient was excluded from further
analysis. However, Neal et al. [22] also performed IRE treat-
ments using only two electrodes in prostate cancer patients
(n=2) that did show PA ablation zones of 1.14 cm3 and
2.46 cm3. This may indicate that the incomplete ablation
was not due to the low number of used electrodes, and the
cause of the required exclusion of this patient remains
unknown.
The close matches of T2MRI, DCE-MRI and CEUS
with PA confirm the accuracy of these imaging modalities
in rendering the ablation zone. The latter two modalities
are based on tissue perfusion and both modalities clearly
s how a lo s s o f e nh an c emen t t h a t r e p r e s e n t s
devascularisation and thus tissue destruction. Since the
PA showed mainly end-stage fibrotic tissue, the destruc-
tion of tissue 4 weeks post-IRE is reasonably representing
the long-term effects. So, ablation effects may be reason-
ably measurable by these imaging modalities.
Conclusion
T2MRI, and CEUS are feasible imaging modalities to visual-
ize the IRE ablation effects in 3D with a strong Pearson’s
correlation of r=0.88 and r=0.80, respectively, compared
with histopathology. Grey-scale US is insufficient for
assessing IRE ablation volumes. mpMRI and CEUS should
be used in future research for the evaluation of IRE effects of
ablation in focal therapy for prostate cancer.
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